8-K: Myomo Reports Strong Q4 and Full Year 2023 Results, Driven by Medicare Expansion

Myomo, a wearable medical robotics company, announced a record backlog and revenue growth in Q4 2023, fueled by the inclusion of Medicare Part B patients and increased demand for their MyoPro device.

Summary

• Myomo reported a 18% increase in total revenue for the fourth quarter of 2023, reaching $4.8 million, compared to the same period in 2022.
• The company's product revenue for the full year 2023 was $17.5 million, a 20% increase year-over-year, and total revenue reached $19.2 million, up 24% from 2022.
• Myomo achieved a record backlog of 230 patients as of December 31, 2023, a 40% increase from the previous year, which includes 44 Medicare Part B patients.
• The company's gross margin for Q4 2023 was 65.3%, a slight increase from 65.0% in Q4 2022, while the full year gross margin was 68.5%, up from 65.9% in 2022.
• Myomo's operating loss for the full year 2023 was $8.2 million, an improvement from the $10.7 million loss in 2022.
• The company's net loss for the full year 2023 was $8.1 million, or $0.28 per share, compared to a net loss of $10.7 million, or $1.52 per share, in 2022.
• Adjusted EBITDA for the full year 2023 was $(7.0) million, compared to $(9.3) million for 2022.
• Myomo added 381 new candidates to the patient pipeline in Q4 2023, a 17% increase, bringing the total pipeline to 1,042 patients as of December 31, 2023, an 18% increase year-over-year.
• The cost per pipeline add decreased by 16% to $2,246 in Q4 2023.
• As of December 31, 2023, Myomo had $8.9 million in cash, cash equivalents, and short-term investments, which increased to approximately $14.3 million after a January 2024 equity offering.

Sentiment

Score: 8

Explanation: The document presents a generally positive outlook with strong revenue growth, a record backlog, and improved financial metrics. The inclusion of Medicare Part B patients is a significant catalyst for future growth. While the company is still operating at a loss, the trend is positive, and the management's outlook is optimistic. The recent capital raise also provides a financial cushion for expansion.

Positives

• The company experienced significant revenue growth in both Q4 and full year 2023.
• Myomo achieved a record backlog, indicating strong future demand for their products.
• The inclusion of Medicare Part B patients in the backlog is a positive development for future revenue.
• The company's gross margin improved year-over-year, indicating better profitability.
• Myomo's operating and net losses decreased compared to the previous year.
• The patient pipeline continues to grow, suggesting a strong market for their products.
• The cost per pipeline add decreased, indicating improved efficiency in customer acquisition.
• The company's cash position improved after a recent equity offering.
• Myomo has received some payments from Medicare for MyoPro devices, indicating progress in reimbursement.

Negatives

• Myomo continues to operate at a loss, with a net loss of $8.1 million for the full year 2023.
• The company's operating expenses increased in Q4 2023, driven by higher development spending and incentive compensation.
• Adjusted EBITDA remains negative, although it has improved year-over-year.
• The company is still reliant on external financing to fund operations.

Risks

• Myomo's ability to achieve operating cash flow breakeven is dependent on their ability to grow revenues sufficiently.
• The company's revenue is concentrated with a particular insurance payer, which could pose a risk if that payer changes its reimbursement policies.
• Myomo's operations are subject to supply chain disruptions, which could impact their ability to deliver and fit their devices.
• The company's success depends on their ability to maintain and grow market acceptance of their products.
• Myomo faces competition in a highly competitive and evolving industry.
• The company's ability to obtain and maintain regulatory approvals is critical to their success.
• The company's future performance is subject to general market, economic, environmental and social factors.

Future Outlook

Myomo expects first quarter 2024 revenue to be in the range of $4.1 million to $4.3 million, with growth expected to accelerate through the remainder of the year. They anticipate Medicare Part B revenues to become more significant starting in the second quarter. The company aims to hire 50 to 60 new employees by the end of the second quarter to increase capacity and believes they have the opportunity to generate $28 million to $30 million in revenue in 2024, with second half revenues much higher than the first half. They also believe reaching operating cash flow breakeven on a quarterly basis by the fourth quarter of 2024 is achievable.

Management Comments

• Fourth quarter and full year 2023 revenues were in line with our expectations as we continued to post solid gains in all key performance metrics, said Paul R. Gudonis, Myomo's chairman and chief executive officer.
• Our pace in converting pipeline to backlog accelerated during the fourth quarter as 44 Medicare Part B patients were included in the year-end count, resulting in a record backlog of 230 patients as the first quarter began.
• We believe 2024 can be a transformational year for the Company and for Medicare Part B beneficiaries who now have access to the MyoPro.
• Revenues from Medicare Part B patients are expected to be more significant beginning in the second quarter.
• Assuming we can increase capacity as planned, with no supply chain disruptions, we believe we have the opportunity to generate $28 million to $30 million in revenue in 2024, with second half revenues much higher than the first half.
• Assuming this rate of revenue growth, we believe reaching operating cash flow breakeven on a quarterly basis by the fourth quarter of 2024 is achievable.

Industry Context

The announcement reflects a positive trend in the medical robotics industry, where companies are increasingly focusing on innovative solutions for neurological disorders and upper-limb paralysis. The inclusion of Medicare Part B coverage for MyoPro is a significant development, potentially opening up a larger market for the company. This move aligns with the broader industry trend of expanding access to advanced medical technologies through insurance coverage.

Comparison to Industry Standards

• Myomo's 24% year-over-year revenue growth for 2023 is strong compared to many medical device companies, especially those in the robotics space, which often see growth rates in the 10-20% range.
• Companies like Ekso Bionics, which also focuses on exoskeletons, have reported similar challenges in achieving profitability, highlighting the capital-intensive nature of the industry.
• The gross margin of 68.5% for Myomo is competitive within the medical device sector, where margins can vary widely depending on the product and market.
• The increase in backlog by 40% is a positive indicator of future revenue, and the inclusion of Medicare Part B patients is a significant catalyst for growth, similar to how other medical device companies have benefited from expanded insurance coverage.
• Compared to companies like ReWalk Robotics, which also targets mobility solutions, Myomo's focus on upper-limb paralysis and the integration of EMG signals provides a unique value proposition.

Stakeholder Impact

• Shareholders will likely view the results positively due to the strong revenue growth and improved financial metrics.
• Employees may benefit from the company's expansion plans and hiring initiatives.
• Customers, particularly those with Medicare Part B coverage, will have increased access to the MyoPro device.
• Suppliers may see increased demand for their products as Myomo scales up its operations.
• Creditors may view the company's improved financial performance and cash position favorably.

Next Steps

• Myomo plans to increase its clinical, reimbursement, and manufacturing capacity to serve Medicare Part B patients.
• The company aims to hire 50 to 60 new employees by the end of the second quarter of 2024.
• Myomo will continue to focus on converting its patient pipeline into backlog and revenue.
• The company will monitor the reimbursement process for Medicare Part B patients and work to ensure timely payments.
• Myomo will continue to develop and improve its MyoPro product line.

Key Dates

Keywords

Myomo, MyoPro, wearable robotics, medical devices, neurological disorders, upper-limb paralysis, Medicare Part B, reimbursement, revenue, backlog, gross margin, EBITDA, patient pipeline